How Does Gilaey Affect Blood Sugar Levels?
Gilaey (tirzepatide) lowers blood sugar levels primarily by mimicking dual hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—that regulate glucose metabolism. It activates GLP-1 and GIP receptors in the pancreas, boosting insulin release and suppressing glucagon only when blood sugar is high, which reduces post-meal glucose spikes without causing excessive lows.[1]
What Clinical Data Shows on Blood Sugar Control?
In trials like SURPASS-2, patients with type 2 diabetes on Gilaey 15 mg saw average HbA1c drops of 2.3% from baseline (versus 1.9% on semaglutide), alongside fasting blood glucose reductions of about 60 mg/dL. Weekly subcutaneous doses (2.5–15 mg) led to sustained control over 40–52 weeks, with greater effects at higher doses.[1][2]
Does It Raise Risk of Hypoglycemia?
Gilaey rarely causes low blood sugar alone (hypoglycemia incidence <1% in monotherapy trials), as its glucose-dependent action limits insulin overproduction. Risk rises (up to 19%) when combined with insulin or sulfonylureas, requiring dose adjustments.[1][3]
How Quickly Does It Start Lowering Blood Sugar?
Effects begin within hours of the first dose via slowed gastric emptying, but peak HbA1c reductions appear by 8–12 weeks with steady-state levels reached after 4 weeks. Weight loss (up to 22 lbs in 72 weeks) contributes indirectly by improving insulin sensitivity.[1][2]
Comparison to Other GLP-1 Drugs Like Ozempic or Mounjaro
Gilaey's dual GIP/GLP-1 action often outperforms single GLP-1 agonists: it reduced HbA1c more than semaglutide (Ozempic) by 0.4–0.5% and dulaglutide (Trulicity) by up to 1%. Unlike metformin, it doesn't require kidney function checks but shares nausea risks.[1][4]
Sources:
[1] Gilaey Prescribing Information (Eli Lilly)
[2] SURPASS Clinical Trials (NEJM)
[3] FDA Label for Tirzepatide
[4] Head-to-Head Comparison (ADA Journals)